Modality
mRNA
MOA
Cl18.2
Target
PD-1
Pathway
Autophagy
Obesity
Development Pipeline
Preclinical
~Dec 2017
→ ~Mar 2019
Phase 1
Jun 2019
→ Oct 2031
Phase 1Current
NCT07207743
1,185 pts·Obesity
2019-06→2031-10·Active
1,185 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2031-10-065.5y awayInterim· Obesity
Trial Timeline
Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3Q4
P1
Active
Catalysts
Interim
2031-10-06 · 5.5y away
Obesity
Active|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07207743 | Phase 1 | Obesity | Active | 1185 | PFS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-7458 | Johnson & Johnson | Phase 1/2 | PD-1 | |
| Zorivorutinib | Bristol-Myers Squibb | Approved | DLL3 | |
| Pexaosocimab | Daiichi Sankyo | Phase 2 | PD-1 | |
| Elrarapivir | Regeneron | Phase 1 | GIP-R | |
| MRN-8133 | Moderna | Phase 2 | PD-1 | |
| Semazasiran | BeiGene | Phase 1 | PD-1 | |
| HAL-9635 | Halozyme | Phase 2/3 | EZH2 | |
| Rimainavolisib | Illumina | Phase 2 | PD-1 | |
| VKT-6548 | Viking Therapeutics | Phase 2/3 | PD-L1 | |
| Tiratapinarof | Intellia | NDA/BLA | APOC3 |